Abstract CT001: Durable, long-term survival in previously treated patients with advanced melanoma (MEL) who received nivolumab (NIVO) monotherapy in a phase I trial
Year: 2016
Type: conference-abstract
Source: Cancer Research
Authors: F. Stephen Hodi, Harriet Kluger, Mario Sznol, Richard Carvajal, Donald Lawrence, Michael Atkins, John Powderly, William Sharfman, Igor Puzanov, David Smith, Philip Leming, Evan Lipson, Janis Taube, Robert Anders, Christine Horak, Joel Jiang, David McDermott, Jeffrey Sosman, Julie Brahmer, Drew Pardoll, Suzanne Topalian
Institutions: Dana-Farber Cancer Institute, Yale New Haven Hospital, Yale University, Smilow Cancer Hospital, Columbia University Irving Medical Center, Massachusetts General Hospital, Georgetown Lombardi Comprehensive Cancer Center, Carolina BioOncology Institute, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Vanderbilt University Medical Center, University of Michigan, Christ Hospital, Bristol-Myers Squibb (United States), Beth Israel Deaconess Medical Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2499347045